MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Auranofin

CAS No. : 34031-32-8

MCE 站：Auranofin

产品活性：Auranofin (SKF-39162)是硫氧还蛋白还原酶 (TrxR) 的抑制剂，IC₅₀为0.2 μM。Auranofin 表现出抗 SARS-CoV21 的抗病毒活性，对猴肾 Vero E6 细胞的 CC₅₀ 为 4.2 μM。

研究领域：Anti-infection

作用靶点：Bacterial  |  SARS-CoV

In Vitro: Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a number of other diseases including cancer, neurodegenerative disorders. Auranofin induces apoptosis in cells through a Bax/Bak-dependent mechanism associated with selective disruption of mitochondrial redox homeostasis in conjunction with oxidation of Prx3. Auranofin inhibits proliferation and survival of SKOV3 cells in a dose- and time-dependent manner. Auranofin treatment activates the pro-apoptotic caspase-3, increases protein levels of apoptosis-inducing proteins Bax and Bim and reduces the expression of the anti-apoptotic mediator Bcl-2 in SKOV3 cells. Auranofin is a lipophilic gold compound with anti-inflammatory and immunosuppressive properties. Auranofin inhibits the cell growth and induction of mitochondrial apoptosis in PC3 human prostate cancer cells. Treatment with auranofin significantly inhibits cell viability with an IC₅₀ value of 2.5 μM after 24 h.

In Vivo: Prophylactic treatment of adjuvant-induced arthritis rats with auranofin results in a slight reduction in paw edema, a complete normalization of the depressed IL-2 production, and a reduction of the elevated IL-1 production, but has no effect on the depressed IL-3 production.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antibacterial Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Chloroquine  |  Staurosporine  |  Dexamethasone  |  Doxycycline (hyclate)  |  Actinomycin D  |  G-418 disulfate  |  5-Azacytidine  |  Etoposide  |  Mitomycin C  |  CCCP  |  Nigericin sodium salt  |  Resveratrol  |  Tunicamycin  |  Hygromycin B  |  Hydroxychloroquine sulfate  |  Tacrolimus  |  Ionomycin  |  Favipiravir  |  Vancomycin hydrochloride  |  Streptozocin  |  Imatinib  |  Tanespimycin  |  Anisomycin  |  Neomycin sulfate  |  Aloxistatin  |  Thapsigargin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。